A detailed history of Marshall Wace, LLP transactions in Bio N Tech Se stock. As of the latest transaction made, Marshall Wace, LLP holds 112,980 shares of BNTX stock, worth $12.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
112,980
Previous 35,985 213.96%
Holding current value
$12.8 Million
Previous $2.89 Million 364.13%
% of portfolio
0.02%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$78.36 - $124.66 $6.03 Million - $9.6 Million
76,995 Added 213.96%
112,980 $13.4 Million
Q2 2024

Aug 14, 2024

BUY
$80.36 - $102.87 $2.89 Million - $3.7 Million
35,985 New
35,985 $2.89 Million
Q4 2022

Feb 14, 2023

BUY
$118.43 - $186.05 $28.2 Million - $44.2 Million
237,709 Added 164.29%
382,397 $57.4 Million
Q3 2022

Nov 14, 2022

SELL
$127.65 - $183.11 $12 Million - $17.2 Million
-93,784 Reduced 39.33%
144,688 $19.6 Million
Q2 2022

Aug 15, 2022

BUY
$123.25 - $186.24 $21.7 Million - $32.7 Million
175,672 Added 279.73%
238,472 $35.6 Million
Q1 2022

May 16, 2022

SELL
$126.25 - $231.85 $13.4 Million - $24.6 Million
-106,207 Reduced 62.84%
62,800 $10.7 Million
Q4 2021

Feb 14, 2022

BUY
$216.64 - $362.52 $36 Million - $60.3 Million
166,367 Added 6301.78%
169,007 $43.3 Million
Q3 2021

Nov 15, 2021

BUY
$205.93 - $447.23 $543,655 - $1.18 Million
2,640 New
2,640 $721,000
Q2 2021

Aug 13, 2021

SELL
$113.32 - $241.49 $3.68 Million - $7.85 Million
-32,499 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$85.73 - $119.5 $1.22 Million - $1.7 Million
14,193 Added 77.53%
32,499 $3.55 Million
Q4 2020

Feb 16, 2021

BUY
$72.71 - $129.54 $1.33 Million - $2.37 Million
18,306 New
18,306 $1.49 Million
Q3 2020

Nov 16, 2020

SELL
$57.81 - $104.17 $255,867 - $461,056
-4,426 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$38.58 - $66.74 $170,755 - $295,391
4,426 New
4,426 $295,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.4B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.